Precision Biosciences (DTIL) Non-Current Deffered Revenue (2018 - 2025)

Precision Biosciences (DTIL) has reported Non-Current Deffered Revenue for 8 consecutive years, with $20.0 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Non-Current Deffered Revenue fell 24.92% year-over-year to $20.0 million; the TTM figure through Sep 2025 stood at $20.0 million (down 24.92% YoY), while the FY2024 annual figure was $23.3 million, down 68.12% from the prior year.
• Non-Current Deffered Revenue eased to $20.0 million in Q3 2025 per DTIL's latest filing, from $20.2 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $131.2 million in Q1 2021 and bottomed at $20.0 million in Q3 2025.
• Historically, Non-Current Deffered Revenue has averaged $63.6 million across 5 years, with a median of $73.1 million in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue jumped 99.05% — and 2025, when it slumped 72.58%.
• Precision Biosciences' Non-Current Deffered Revenue stood at $67.0 million in 2021, then rose by 23.66% to $82.9 million in 2022, then decreased by 11.81% to $73.1 million in 2023, then plunged by 68.12% to $23.3 million in 2024, then decreased by 14.35% to $20.0 million in 2025.
• Business Quant data shows DTIL's Non-Current Deffered Revenue at $20.0 million in Q3 2025, $20.2 million in Q2 2025, and $20.5 million in Q1 2025.